Naluzotan Hydrochloride
Naluzotan Hydrochloride is in phase II clinicals for the treatment of epilepsy/seizures. This compound was originally discovered by Epix Pharmaceuticals，and now is being co-developed by Proximagen in collaboration with National Institute of Neurological Disorders and Stroke (NINDS) under a collaboration research and development agreement (CRADA).
General Information
Update Date：2016-02-04
- Drug Name：
- Naluzotan Hydrochloride
- Research Code：
- PRX-00023
- Trade Name：
- MOA：
- 5-HT1A receptor agonist
- Indication：
- Epilepsy/Seizures
- Status：
- Phase II (Active)
- Company：
- Epix (Originator) , National Institute of Neurological Disorders and Stroke,Upsher Smith Laboratories
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-02-04
|
Molecular Weight | 523.56 | ||||||||||||
| Formula | C23H38N4O3S • 2HCl | |||||||||||||
| CAS No. |
740873-06-7 (Naluzotan); 740873-07-8 (Naluzotan Dihydrochloride); |
|||||||||||||
| Chemical Name | Acetamide, N-[3-[4-[4-[[(cyclohexylmethyl)sulfonyl]amino]butyl]-1-piperazinyl]phenyl]-, hydrochloride (1:2) | |||||||||||||
| Naluzotan （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||